4D Pharma

4D Pharma Plc is a pharmaceutical company, which engages in the development of live bio therapeutics. It focuses on the research of Microbiome, MicroRx, and MicroDx its proprietary platforms for the discovery of novel live bio therapeutics and the development of its pipeline. The company was founded by Duncan Joseph Peyton on January 10, 2014 and is headquartered in Leeds, the United Kingdom.

The stock price of 4D pharma (NASDAQ: LBPS) increased by over 7% pre-market. This is why it happened.

LBPS Stock Price: Over 7% Increase Pre-Market Explanation

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD; NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces additional positive data from its completed Phase II trial of LBP Blautix® in subjects with irritable bowel syndrome with constipation (IBS-C) or with diarrhea (IBS-D). The data has been presented in a poster session at Digestive Disease Week (DDW), on May 22, 2021, b

4D pharma Presents Additional Positive Results of Phase II Study of Blautix® for the Treatment of Irritable Bowel Syndrome

4D pharma PLC (LON:DDDD NASDAQ:LBPS) said it has provided a more detailed analysis of its Live Biotherapeutic, Blautix, which is both significant and supportive of its continued development as an irritable bowel syndrome treatment. The data, presented as a poster at the medical and scientific conference Digestive Disease Week, builds on the top-line results released last October.

4D pharma "encouraged" after additional analysis of IBS drug data

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announced that it will present data from its Phase II study of single strain LBP Blautix® in patients with irritable bowel syndrome (IBS) subtypes IBS-C and IBS-D in a poster session at Digestive Disease Week (DDW) 2021, taking place virtually May 21-23, 2021. Details of the po

4D pharma to Present Additional Data from Phase II Study of Blautix for the Treatment of Irritable Bowel Syndrome at Digestive Disease Week (DDW) 2021

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD; NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces a collaboration with Parkinson's UK, a non-profit organization focused on advancing the understanding of Parkinson's disease and improving treatments, to establish a Patient Advisory Board. The Patient Advisory Board (PAB) will be comprised of people living with Parki

4D pharma Collaborates With Parkinson's UK to Establish Patient Advisory Board

Leeds, UK, April 01, 2021 (GLOBE NEWSWIRE) -- 4D pharma plc (AIM: DDDD, NASDAQ: LBPS) (“4D”, the “Company” or, together with its subsidiaries, the “Group”), a pharmaceutical company leading the development of Live Biotherapeutics, is pleased to announce the final results for the Group for the year ended 31 December 2020.

Final Results for the year ended 31 December 2020

4D pharma PLC (LON:DDD, NASDAQ:LBPS) hailed 2020 as a “transformational year” for the company. In its full-year results statement, the company listed the publication of the first proof-of-concept data for MRx0518 in last-line cancers and the journey towards a listing on NASDAQ as highlights of the year.

4D pharma highlights significant progress made in 2020

Longevity Acquisition Corp

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (Nasdaq: LBPS; AIM: DDDD) ("4D pharma" or the "Company"), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome - today announced completion of its merger (“the Merger”) with Longevity Acquisition Corporation ("Longevity")(Nasdaq: LOAC). 4D pharma American Depositary Shares (“ADSs”) are expected to begin trading today on the Nasdaq Global Market under the ticker s

4D pharma Announces Completion of Merger With Longevity Acquisition Corporation

LEEDS, United Kingdom--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD) ("4D" or the "Company"), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, is pleased to announce that its business combination with Longevity Acquisition Corporation, details of which were announced on 22 October 2020 (the "Merger"), has now become effective. 4D pharma's existing Board of Directors and management team will continue to lead

News for 4D Pharma Stock (LBPS)